Trial Profile
SGN-70 efficacy, pharmacodynamics, pharmacokinetics and tolerability in patients and volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Sep 2022
Price :
$35
*
At a glance
- Drugs Vorsetuzumab (Primary)
- Indications Autoimmune disorders; Plaque psoriasis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 02 Mar 2011 New trial record